Common Stock, par value $0.001 per share
- Symbol
- STXS
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Stereotaxis, Inc.
STXSNYSE_AMERICANEQUITYCurrent
Results of Operations and Financial Condition
Item Results 2.02 of Operations and Financial Condition On August 11, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2026 second quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.
Press release in this filing
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates →Recent company filings
- Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesNov 10, 2026
- EFFECT filingAug 13, 2026
- EFFECT filingAug 13, 2026
- 424B3 filingAug 13, 2026
- 424B3 filingAug 13, 2026
Registered securities in this filing
STEREOTAXIS, INC. · 8-K · Filed 2026-08-11
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item Results
2.02 of Operations and Financial Condition
On
August 11, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting
forth its financial results for the 2026 second quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto,
and the statements contained therein are incorporated by reference herein.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially First GenesisX robotic system purchase by US hospital to be installed this fall Multiple Synchrony digital operating room systems sold and installed following FDA clearance in April Completed previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures St. Louis, MO, August 11, 2026 (Globe Newswire) - Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026. “Stereotaxis has reached an important commercial inflection point. Following years of product development and regulatory milestones, the Company’s expanded robotic platform is now generating accelerating commercial adoption across multiple product lines,” said David Fischel, Stereotaxis Chairman and CEO. “Over the last several years we advanced an exciting ecosyste…
Open exhibit ↗